When was Addition Therapeutics founded?

Addition Therapeutics was founded in 2021 and raised its 1st funding round 4 years after it was founded.

Where is Addition Therapeutics located?

Addition Therapeutics is headquartered in San Francisco, United States.

Who is the current CEO of Addition Therapeutics?

Ron Park of Addition Therapeutics.

How many employees does Addition Therapeutics have?

As of Jun 30, 2026, the latest employee count at Addition Therapeutics is 68.

Is Addition Therapeutics a funded company?

Addition Therapeutics is a funded company, having raised a total of $***** in its 1st and only funding round, a Series D round on Dec 11, 2025.

When was the latest funding round of Addition Therapeutics?

Addition Therapeutics' latest funding was a $***** Series D round on Dec 11, 2025, with participation from 6 investors. Its primary sector is Genomics. In United States, the Genomics sector has seen $1.35B in funding in 2026 to date.

Where does Addition Therapeutics rank among its competitors?

Addition Therapeutics ranks 135th amongst 587 active competitors, of which 216 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Addition Therapeutics, which secured $106M in Dec, 2025.

Who are the top competitors of Addition Therapeutics?

Addition Therapeutics' top competitors include Alnylam, Spark Therapeutics and Forge Biologics. Among them, Addition Therapeutics secured the most recent funding round in December, 2025.

Addition Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of RNA-mediated genetic medicines. The company uses PRINT technology to develop RNA-only therapeutics to transform genetic medicine.

Website: additiontx.com
Email ID: *****@additiontx.com

Key Metrics

Founded Year

2021

Location

San Francisco, United States

Stage

Series D

Total Funding

$106M in 1 round

Latest Funding Round

Series D, Dec 11, 2025, $*****

Investors

Abingworth & 5 more

Ranked

135^th among 587 active competitors

Employee Count

68 as on Jun 30, 2026

Investment & Acquisitions

Bakar Labs

Similar Companies

Alnylam & 727 more

View Addition Therapeutics' full profile

Addition Therapeutics has raised a total funding of $106M over 1 round. Its latest funding round was a Series D round on Dec 11, 2025 for $*****. 6 investors participated in its latest round. Addition Therapeutics has 6 institutional investors.

Here is the list of recent funding rounds of Addition Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 11, 2025	4720137	Series D	9828071	5801358	7325073	6120527

Access funding benchmarks and valuations. Sign up today!

View details of Addition Therapeutics's funding rounds and investors

Addition Therapeutics' employee count trend

Addition Therapeutics has 68 employees as of Jun 26. Here is Addition Therapeutics's employee count trend over the years:

Employee count trend for Addition Therapeutics

Uncover Addition Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Addition Therapeutics include Alnylam, Spark Therapeutics and Forge Biologics. Here is the list of Top 10 competitors of Addition Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
2nd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
3rd	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	Aisling Capital, RA Capital Management & 7 others	70/100
4th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
5th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, MassChallenge & 19 others	70/100
6th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
7th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	F-Prime Capital, Adage Capital Management ... & 10 others	69/100
8th	Generation Bio 2016, Cambridge (United States), Acquired	Developer of gene therapies for rare liver and eye diseases	$236M	T. Rowe Price, Fidelity Investments & 9 others	69/100
9th	ElevateBio 2018, Cambridge (United States), Series D	Provider of transnational research for portfolio of cell and gene therapy	$1.25B	Matrix Capital Management, EDBI & 16 others	68/100
10th	Krystal Biotech 2015, Pittsburgh (United States), Public	Developer of genetic medicines to treat rare diseases	$11.3M	Frazier Life Sciences, Danforth Advisors & 2 others	67/100
135th	Addition Therapeutics 2021, San Francisco (United States), Series D	Developer of RNA-mediated genetic medicines	$106M	Abingworth, Gates & 4 others	48/100